Viking Therapeutics, Inc. (VKTX) — Analyst outlook / Analyst consensus target is. Based on 23 analyst ratings, the consensus is bullish — 1 Strong Buy, 21 Buy, 1 Hold.
The consensus price target is $103.00 (low: $99.00, high: $107.00), representing an upside of 190% from the current price $35.52.
Analysts estimate Earnings Per Share (EPS) of $-0.96 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.01 vs est $-0.96 (missed -4.9%). 2025: actual $-3.19 vs est $-2.72 (missed -17.2%). Analyst accuracy: 90%.
VKTX Stock — 12-Month Price Forecast
$103.00
▲ +189.98% Upside
Average Price Target
Based on 23 Wall Street analysts offering 12-month price targets for Viking Therapeutics, Inc., the average price target is $103.00, with a high forecast of $107.00, and a low forecast of $99.00.
The average price target represents a +189.98% change from the last price of $35.52.
Highest Price Target
$107.00
Average Price Target
$103.00
Lowest Price Target
$99.00
VKTX Analyst Ratings
Buy
Based on 23 analysts giving stock ratings to Viking Therapeutics, Inc. in the past 3 months
EPS Estimates — VKTX
90%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.01
vs Est –$0.96
▼ 4.7% off
2025
Actual –$3.19
vs Est –$2.72
▼ 14.7% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — VKTX
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
